RRM2 has been previously reported as a master driver of tumor aggressiveness and a biomarker of poor prognosis in several cancer including glioma, oral cancer, lung cancer, colorectal cancer, prostate cancer, endometrial cancer and cervical cancer [18, 31–36]. Here, RRM2 is linked to cervical cancer.